Leonteq Securities AG’s Keros Therapeutics KROS Stock Holding History

Leonteq Securities AG’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-270	Closed	-$13K	–	1270
2022 Q4	$13K	Hold	270	–	–	﹤0.01%	1023
2022 Q3	$10.2K	Hold	270	–	–	﹤0.01%	1054
2022 Q2	$7.46K	Hold	270	–	–	﹤0.01%	1124
2022 Q1	$14.7K	Hold	270	–	–	﹤0.01%	1050
2021 Q4	$15.8K	Buy	+270	New	+$13.5K	﹤0.01%	1097

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Leonteq Securities AG's KROS Position: Q1 2023 in Review

Leonteq Securities AG sold out of Keros Therapeutics (KROS) in Q1 2023, closing a stake of 270 shares — an estimated $13K sold.

Leonteq Securities AG first reported a position in KROS in Q4 2021 and held it in 5 quarters. The position peaked at $15.8K in Q4 2021. 129 funds tracked by Wall St. Rank hold KROS as of Q1 2023.

Leonteq Securities AG reported no remaining Keros Therapeutics position as of Q1 2023 after selling out during the quarter.
Leonteq Securities AG sold 270 Keros Therapeutics shares in Q1 2023, an estimated $13K.
Leonteq Securities AG first reported a position in Keros Therapeutics in Q4 2021 and held it in 5 quarters.
Leonteq Securities AG's Keros Therapeutics position peaked at $15.8K in Q4 2021.
129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2023.

Based on Leonteq Securities AG's 13F filing for Q1 2023, filed 11 Mar 2026.